Summary of disease control, spirometry, airway inflammation and treatment at the time of transition and during the follow-up at the Adult Center
| Disease control, instrumental data and treatment | Case 1 | Case 2 | Case 3 | Case 4 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow-up | ||
| C-ACT | 25 | 25 | 22 | 25 | 22 | 23 | 22 | 24 | |
| Asthma attacks* | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | |
| FEV1 (% pred) | 68 | 59 | 88 | 89 | 98 | 112 | 75 | 81 | |
| FVC (% pred) | 90 | 80 | 101 | 96 | 106 | 113 | 97 | 95 | |
| FEV1/FVC (%) | 66 | 62.9 | 84 | 81 | 82 | 87 | 77 | 73 | |
| FEF25-75 (% pred) | 40 | 34 | 68 | 78 | 87 | 112 | 57 | 52 | |
| FeNO (ppb) | 40 | 20 | 53 | 60 | 17 | 18 | 55 | 42 | |
| Treatment | Flu/Sal + LTRA + OMA | Bud/Form + LTRA +DUPI | Bud/Form + LTRA +MEPO | Bud/Form + LTRA +MEPO | Bud/Form + MEPO | Bud/Form + MEPO | Bud/Form + OMA | Bud/Form + DUPI | |
* Cumulative number of asthma attacks during the years after transition. C-ACT: childhood asthma control test; FEV1: forced expiratory volume during the first second; FVC: forced vital capacity; FEF25–75: forced mid-expiratory flow; FeNO: fractional exhaled nitric oxide; Flu/Sal: fluticasone propionate/salmeterol; LTRA: Leukotriene receptor antagonist; OMA: omalizumab; Bud/Form: budesonide/formoterol; DUPI: dupilumab; MEPO: mepolizumab